Brief: Acura Pharmaceuticals says exploring strategic alternatives
Jan 3 (Reuters) - Acura Pharmaceuticals Inc ACUR.O
* Acura Pharmaceuticals exploring strategic alternatives
* Acura Pharmaceuticals - alternatives to a sale of company
include a capital raising transaction, a licensing transaction
and a sale of certain assets
* Acura Pharmaceuticals Inc - has retained Roth Capital
Partners to assist in financing and strategic alternatives
process
* Exploring a full range of financing and strategic
alternatives, including a possible sale of company
Source text for Eikon: ID:nGNXNNSWLa
Further company coverage: ACUR.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Acura Pharmaceuticals
See all newsBrief: Acura Pharmaceuticals Received A $250,000 Loan From Abuse Deterrent Pharma, LLC on October 11
Brief: Acura Pharmaceuticals Inc Receives $200,000 Loan From Abuse Deterrent Pharma
Brief: Acura Pharmaceuticals Received $250,000 Loan From AD Pharma For Operations Through End Of April 2023
Brief: Acura Pharmaceuticals, AD Pharma Amend License to LIMITx LTX-03
Insight: Novavax bosses cash out for $46 mln with COVID-19 vaccine trials still under way